Aveksim's cinnarizine

General characteristics. Structure:

Active ingredient: 25 mg of cinnarizine.

Excipients: potato starch, polyvinylpirrolidone, povidone low-molecular, magnesium stearate, lactose, silicon dioxide colloid (aerosil).

Pharmacological properties:

Pharmacodynamics. The selection blocker of slow calcium channels, reduces receipt in cells of calcium ions and reduces their keeping in depot of a plasmolemma, reduces a tone of smooth muscles of arterioles. Directly influencing smooth muscles of vessels, reduces their reaction to biogenic substances (adrenaline, noradrenaline, dopamine, angiotensin, vasopressin). Has vasodilating effect (especially concerning brain vessels), without having significant effect on the ABP.

Shows moderate antihistaminic activity, reduces excitability of a vestibular mechanism, lowers a tone of a sympathetic nervous system. Increases elasticity of membranes of erythrocytes, their deformability, reduces viscosity of blood. Increases resistance of muscles to a hypoxia.

Pharmacokinetics. It is soaked up in a stomach and intestines. Cmax in a blood plasma after intake in 1-3 h. Communication with proteins of plasma makes 91%.

It is completely metabolized in a liver (by means of a glyukuronirovaniye). T1/2 is equal to 4 h. It is removed in the form of metabolites 1/3 - kidneys and 2/3 - with a fecal masses.

Indications to use:

— symptoms of cerebrovascular insufficiency (dizziness, sonitus, headache, memory disturbances, decrease in concentration of attention);

— vestibular disturbances (including Menyer's disease: dizziness, sonitus, nystagmus, nausea and vomiting of a labyrinth origin);

— prevention of kinetoz ("a road disease" - sea and aeroembolism);

— migraine (prevention of attacks);

— disturbances of peripheric circulation: a Raynaud's disease, the "alternating" lameness, a Crocq's disease, trophic disturbances (including trophic and varicose ulcers).

Route of administration and doses:

Inside, after food. At insufficiency of cerebral circulation - on 25 mg of 3 times/days.

At disturbance of peripheric circulation - on 50-75 mg of 3 times/days.

At vestibular disturbances - on 25 mg of 3 times/days.

The maximum recommended dose should not exceed 225 mg (9 tablets) a day. A course of treatment from several weeks to several months.

At a kinetoza (a "road" disease): the adult - on 25 mg for half an hour before the road (if necessary repeated reception of 25 mg in 6 h), for children of 5 years - 1/2 doses, recommended to adults.

At high sensitivity to drug treatment is begun about 1/2 doses, increasing it gradually.

Features of use:

Use for children. Drug use is forbidden to children under 5 years. At a kinetoza (a "road" disease) to children 5 years - 1/2 doses, recommended to adults are more senior.

The patient with Parkinson's disease drug is appointed only in case advantages of treatment surpass by cinnarizine in the importance possible deterioration in a current of a basic disease.

In an initiation of treatment can cause drowsiness therefore alcohol intake and simultaneous use of depressants of TsNS demands care.

Due to the antihistaminic effect purpose of cinnarizine should be stopped in 4 days prior to conducting allergy skin test. Cinnarizine can affect result at anti-doping control of athletes (false positive result).

At a lactose intolerance it is necessary to consider that 1 tablet contains 175 mg of lactose.

Influence on ability to drive the car and other working mechanisms. Drowsiness development, especially in the beginning treatments therefore it is necessary to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions is possible. At prolonged use carrying out control laboratory inspection of function of a liver, kidneys is recommended, to peripheral blood.

Side effects:

From a nervous system: drowsiness, fatigue, headache, extrapyramidal frustration (tremor of extremities and increase in a muscle tone, hypokinesia), depression.

From the alimentary system: dryness in a mouth, pain in epigastric area, dyspepsia, cholestatic jaundice.

From integuments: perspiration, development of a volchanochnopodobny syndrome, red flat deprive (extremely seldom), skin rash.

Others: allergic reactions, increase in body weight.

Interaction with other medicines:

Strengthens the oppressing action on TsNS of alcohol, sedatives, tricyclic antidepressants. Due to the existence of antihistaminic effect, cinnarizine can affect result of anti-doping control of athletes (a false positive take), and also can level positive reactions when conducting skin diagnostic tests (in 4 days prior to a research treatment should be cancelled).

Contraindications:

— hypersensitivity;

— pregnancy;

— lactation period;

— children's age up to 5 years.

With care at Parkinson's disease.

Overdose:

Symptoms: strengthening of expressiveness of side effects, decrease in the ABP, vomiting, coma.

Treatment: the specific antidote does not exist, a gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

Drug should be stored in dry, protected from light and the place, unavailable to children. Period of validity 2 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

10 pieces - planimetric strip packagings (1) - packs cardboard.
10 pieces - planimetric strip packagings (2) - packs cardboard.
10 pieces - planimetric strip packagings (3) - packs cardboard.
10 pieces - planimetric strip packagings (4) - packs cardboard.
10 pieces - planimetric strip packagings (5) - packs cardboard.